No Data
TD Cowen Maintains SpringWorks Therapeutics(SWTX.US) With Buy Rating, Maintains Target Price $63
TD Cowen Remains a Buy on Springworks Therapeutics (SWTX)
Barclays Maintains SpringWorks Therapeutics(SWTX.US) With Buy Rating, Maintains Target Price $63
BofA Securities Maintains SpringWorks Therapeutics(SWTX.US) With Buy Rating, Maintains Target Price $55
SWTX Announces 2024 Preliminary Results, 2025 Goals, Stock Down
A Quick Look at Today's Ratings for SpringWorks Therapeutics(SWTX.US), With a Forecast Between $55 to $63